255 related articles for article (PubMed ID: 25826624)
1. Thermosensitive, near-infrared-labeled nanoparticles for topotecan delivery to tumors.
Rosca EV; Wright M; Gonitel R; Gedroyc W; Miller AD; Thanou M
Mol Pharm; 2015 May; 12(5):1335-46. PubMed ID: 25826624
[TBL] [Abstract][Full Text] [Related]
2. Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.
Centelles MN; Wright M; So PW; Amrahli M; Xu XY; Stebbing J; Miller AD; Gedroyc W; Thanou M
J Control Release; 2018 Jun; 280():87-98. PubMed ID: 29723616
[TBL] [Abstract][Full Text] [Related]
3. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting nanocarrier system based on thermosensitive liposomes and gold nanorods for cancer thermo-chemotherapy.
Yu M; Guo F; Tan F; Li N
J Control Release; 2015 Oct; 215():91-100. PubMed ID: 26256259
[TBL] [Abstract][Full Text] [Related]
5. Liposomal drug delivery systems: from concept to clinical applications.
Allen TM; Cullis PR
Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
[TBL] [Abstract][Full Text] [Related]
6. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional liposomes having target specificity, temperature-triggered release, and near-infrared fluorescence imaging for tumor-specific chemotherapy.
Kono K; Takashima M; Yuba E; Harada A; Hiramatsu Y; Kitagawa H; Otani T; Maruyama K; Aoshima S
J Control Release; 2015 Oct; 216():69-77. PubMed ID: 26264832
[TBL] [Abstract][Full Text] [Related]
8. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
10. Thermosensitive Liposomes for Image-Guided Drug Delivery.
Haemmerich D; Motamarry A
Adv Cancer Res; 2018; 139():121-146. PubMed ID: 29941102
[TBL] [Abstract][Full Text] [Related]
11. Surface-active liposomes for targeted cancer therapy.
Sofou S
Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032
[TBL] [Abstract][Full Text] [Related]
12. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
13. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.
Agarwal A; Mackey MA; El-Sayed MA; Bellamkonda RV
ACS Nano; 2011 Jun; 5(6):4919-26. PubMed ID: 21591812
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells.
Taratula O; Dani RK; Schumann C; Xu H; Wang A; Song H; Dhagat P; Taratula O
Int J Pharm; 2013 Dec; 458(1):169-80. PubMed ID: 24091153
[TBL] [Abstract][Full Text] [Related]
15. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
16. Thermosensitive liposomes with higher phase transition temperature for targeted drug delivery to tumor.
Chen J; He CQ; Lin AH; Gu W; Chen ZP; Li W; Cai BC
Int J Pharm; 2014 Nov; 475(1-2):408-15. PubMed ID: 25218394
[TBL] [Abstract][Full Text] [Related]
17. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
Al-Jamal WT; Kostarelos K
Acc Chem Res; 2011 Oct; 44(10):1094-104. PubMed ID: 21812415
[TBL] [Abstract][Full Text] [Related]
18. Companion Diagnostic
Lee H; Gaddy D; Ventura M; Bernards N; de Souza R; Kirpotin D; Wickham T; Fitzgerald J; Zheng J; Hendriks BS
Theranostics; 2018; 8(9):2300-2312. PubMed ID: 29721081
[TBL] [Abstract][Full Text] [Related]
19. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.
Patankar NA; Pritchard J; van Grinsven M; Osooly M; Bally MB
Clin Cancer Res; 2013 Feb; 19(4):865-77. PubMed ID: 23303216
[TBL] [Abstract][Full Text] [Related]
20. Liposome-nanoparticle hybrids for multimodal diagnostic and therapeutic applications.
Al-Jamal WT; Kostarelos K
Nanomedicine (Lond); 2007 Feb; 2(1):85-98. PubMed ID: 17716195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
